Itacitinib treatment for LR GVHD

Etra AM, Capellini A, Alousi AM, et al. Effective Treatment of Low Risk Acute GVHD With Itacitinib Monotherapy. Blood. 2022; (doi: 10.1182/blood.2022017442).

Treating low risk (LR) acute graft versus host disease (GVHD) with itacitinib monotherapy seems to be as effective as treatment with systemic corticosteroids (SCS), with a lower risk of severe infection, according to new research. For the multicenter, Phase II trial, 70 patients with LR GVHD received itacitinib 200 mg/d for 28 days — with responders able to receive a second 28-day cycle — while 140 matched controls received SCS. By day seven, 81% of the itacitinib patients had responded, compared with 66% of the controls. Response rates for both groups at 28 days were high, at 89% and 86%, respectively, with low rates of symptomatic flares. At 90 days, rates of serious infection were lower in the itacitinib group, at 27% vs. 42% in the controls, the result of fewer viral and fungal infections. Both groups had similar rates of grade ≥3 cytopenias, although leukopenia in the itacitinib group was much less severe compared with the control group. At one year, there were no substantial differences between groups in terms of non-relapse mortality, relapse, chronic GVHD, and survival.

Read More

Tags: patient care, GVHD, Relapse, cells, Cellular therapy, Survival, Research, Cell Transplantation, cell therapy, itacitinib, response rate, transplantation and cellular therapy, transplatation, graft-versus-host